摘要
目的观察多西他赛在淋巴结N2的Ⅲ期鼻咽癌放疗增敏作用及毒副反应。方法纳入淋巴结为N2的48例Ⅲ期鼻咽癌患者，采用随机数字表法分为同步放化疗组和单纯放疗组各24例。两组患者均采用全程调强放射治疗（intensitymodulatedradiationtherapy，IMRT），鼻咽部剂量70—76Gy／7—8w，颈部淋巴结转移灶剂量60—70Gy／6—7w。在此基础上，同步放化疗组每周给予多西他赛一次（20-25mg／m。）。结果同步放化疗组完全缓解（CR）83．3％，而单纯放疗组为66．7％，差异有统计学意义（P〈0．05）。毒副反应主要表现为白细胞减少口腔黏膜反应。结论多西他赛作为放疗增敏剂具有较好的临床增敏作用，能提高淋巴结N2的Ⅲ期鼻咽癌患者的有效率，且毒副作用可以耐受。
Objective To evaluate the sensitizing efficiency and toxicity of docetaxel in patients with stage Ill-lymph node N2 nasopharyngeal cancer treated with chemo-radiotherapy. Methods Forty-eight patients with stage -lymph node N2 nasopharyngeal carcinoma were randomly divided into concurrent ehemo-radiotherapy group and radiotherapy alone group,24 cases in each group. In- tensity modulated radiation therapy （IMRT） was applied to the both groups. Radiation doses were 70 - 76 Gy/7 - 8 week and 70-76 Gy/7 -8 week at nasopharyngeal location and lymph node metastases of the neck, respectively. On this basis, doeetaxel （20-25 mg/ mz ） was added weekly to the concurrent ehemo-radiotherapy group. Results The rate of complete remission （CR） in the coneurrent chemo-radiotherapy group was 83.3% ,while the radiotherapy alone group was 66.7% （P 〈 0. 05 ）. The major toxic reactions were leu- kopenia and reaction of oral mt/cosa. Conclusion Docetaxel as a radiation sensitizer agent with better clinical sensitizing effeet can in- creases the treatment efficieney for patients with stage III-lymph node N2 nasopharyngeal carcinoma, and the side effects of the concur- rent chemo-radiotherapy can he tolerated.
出处
《实用医院临床杂志》
2014年第1期94-96,共3页
Practical Journal of Clinical Medicine
关键词
鼻咽癌
同步放化疗
多西他赛
Nasopharyngeal carcinoma
Concurrent chemo-radiotherapy
Docetaxel
